Diligence memo · auto-generated · as of July 2, 2026
Celsius Therapeutics, Inc.
Celsius Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Celsius Therapeutics, Inc. operates in Pharma, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Celsius Therapeutics, Inc. has raised $48M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $48M on 2018-05-14.
Most recent recorded round closed around 2018-05-14.
Valuation (modeled)modeled
Provath models Celsius Therapeutics, Inc. at approximately $1.7B (range $156M–$4.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.05× the median modeled value of Series C Pharma companies in 2016–2018 (5 peers) — value vs value, same stage and era. Within the normal band (105% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 8.1 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 85% of Pharma peers (310 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Prevail Therapeutics Inc., Akero Therapeutics, Inc., Advanced Cardiac Therapeutics Inc, Ovid Therapeutics Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.